Table 3 The relationship between ferroportin expression and hepatocellular carcinoma (HCC) clinical characteristics (n (%))
From: RETRACTED ARTICLE: Ferroportin in the progression and prognosis of hepatocellular carcinoma
Characteristic | Expression level of ferroportin | P | |||
|---|---|---|---|---|---|
| Â | 0 | 1 to 3 | 4 to 5 | 6 to 7 | Â |
Intrahepatic metastasis | Â | Â | Â | Â | 0.008* |
  + | 10 (83.3) | 2(16.7) | 0 (0) | 0 (0) | |
  - | 33 (68.8) | 7(14.6) | 6(12.5) | 2(4.2) | |
Portal vein invasion | Â | Â | Â | Â | 0.007* |
  + | 10 (90.9) | 1 (9.1) | 0 (0) | 0 (0) | |
  - | 33 (67.3) | 8 (16.3) | 6 (12.2) | 2 (4.1) | |
Edmondson-Steiner grading | Â | Â | Â | Â | 0.02* |
  I to II | 22 (64.7) | 5 (14.7) | 5 (14.7) | 2 (5.9) | |
  III to IV | 21(80.8) | 4 (15.4) | 1 (3.8) | 0 (0) | |
TNM staging | Â | Â | Â | Â | 0.01* |
  I to II | 22 (64.7) | 5 (14.7) | 5 (14.7) | 2 (5.9) | |
  III to IV | 21 (80.8) | 4 (15.4) | 1 (3.8) | 0(0) | |
AFP (ng/mL) | Â | Â | Â | Â | 0.18 |
≤400 | 7 (14.3) | 24(49) | 15 (30.6) | 3 (6.1) | |
>400 | 1 (9.1) | 5(45.5) | 4(36.4) | 1 (9.1) | Â |